Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):2009–2011. doi: 10.1128/aac.33.11.2009

Mechanism of La Crosse virus inhibition by ribavirin.

L F Cassidy 1, J L Patterson 1
PMCID: PMC172805  PMID: 2610511

Abstract

The effect of ribavirin on the growth and replication of La Crosse virus was examined. The data suggest that low concentrations of ribavirin have a marked effect on the initial steps of La Crosse virus transcription. The therapeutic potential of ribavirin in the treatment of human California encephalitis serotype infections is discussed in light of these findings.

Full text

PDF
2009

Images in this article

2010Image
on p.2010
2010Image
on p.2010
2011Image
on p.2011

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bellocq C., Kolakofsky D. Translational requirement for La Crosse virus S-mRNA synthesis: a possible mechanism. J Virol. 1987 Dec;61(12):3960–3967. doi: 10.1128/jvi.61.12.3960-3967.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bellocq C., Raju R., Patterson J., Kolakofsky D. Translational requirement of La Crosse virus S-mRNA synthesis: in vitro studies. J Virol. 1987 Jan;61(1):87–95. doi: 10.1128/jvi.61.1.87-95.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cabradilla C. D., Jr, Holloway B. P., Obijeski J. F. Molecular cloning and sequencing of the La Crosse virus S RNA. Virology. 1983 Jul 30;128(2):463–468. doi: 10.1016/0042-6822(83)90271-4. [DOI] [PubMed] [Google Scholar]
  4. Crumpacker C., Bubley G., Lucey D., Hussey S., Connor J. Ribavirin enters cerebrospinal fluid. Lancet. 1986 Jul 5;2(8497):45–46. doi: 10.1016/s0140-6736(86)92590-0. [DOI] [PubMed] [Google Scholar]
  5. Fernandez-Larsson R., O'Connell K., Koumans E., Patterson J. L. Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction. Antimicrob Agents Chemother. 1989 Oct;33(10):1668–1673. doi: 10.1128/aac.33.10.1668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ferrara E. A., Oishi J. S., Wannemacher R. W., Jr, Stephen E. L. Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother. 1981 Jun;19(6):1042–1049. doi: 10.1128/aac.19.6.1042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kolakofsky D., Bellocq C., Raju R. The translational requirement for La Crosse virus S-mRNA synthesis. Cold Spring Harb Symp Quant Biol. 1987;52:373–379. doi: 10.1101/sqb.1987.052.01.043. [DOI] [PubMed] [Google Scholar]
  8. Krug R. M. Priming of influenza viral RNA transcription by capped heterologous RNAs. Curr Top Microbiol Immunol. 1981;93:125–149. doi: 10.1007/978-3-642-68123-3_6. [DOI] [PubMed] [Google Scholar]
  9. Leppert M., Rittenhouse L., Perrault J., Summers D. F., Kolakofsky D. Plus and minus strand leader RNAs in negative strand virus-infected cells. Cell. 1979 Nov;18(3):735–747. doi: 10.1016/0092-8674(79)90127-2. [DOI] [PubMed] [Google Scholar]
  10. Obijeski J. F., Bishop D. H., Murphy F. A., Palmer E. L. Structural proteins of La Crosse virus. J Virol. 1976 Sep;19(3):985–997. doi: 10.1128/jvi.19.3.985-997.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ogle J. W., Toltzis P., Parker W. D., Alvarez N., McIntosh K., Levin M. J., Lauer B. A. Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis. 1989 Apr;159(4):748–750. doi: 10.1093/infdis/159.4.748. [DOI] [PubMed] [Google Scholar]
  12. Patterson J. L., Holloway B., Kolakofsky D. La Crosse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. J Virol. 1984 Oct;52(1):215–222. doi: 10.1128/jvi.52.1.215-222.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Patterson J. L., Kolakofsky D. Characterization of La Crosse virus small-genome transcripts. J Virol. 1984 Mar;49(3):680–685. doi: 10.1128/jvi.49.3.680-685.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Porterfield J. S., Casals J., Chumakov M. P., Gaidamovich S. Y., Hannoun C., Holmes I. H., Horzinek M. C., Mussgay M., Oker-Blom N., Russell P. K. Bunyaviruses and Bunyaviridae. Intervirology. 1975;6(1):13–24. doi: 10.1159/000149449. [DOI] [PubMed] [Google Scholar]
  15. Raju R., Kolakofsky D. Unusual transcripts in La Crosse virus-infected cells and the site for nucleocapsid assembly. J Virol. 1987 Mar;61(3):667–672. doi: 10.1128/jvi.61.3.667-672.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rossier C., Raju R., Kolakofsky D. LaCrosse virus gene expression in mammalian and mosquito cells. Virology. 1988 Aug;165(2):539–548. doi: 10.1016/0042-6822(88)90598-3. [DOI] [PubMed] [Google Scholar]
  17. Sanger F., Coulson A. R. The use of thin acrylamide gels for DNA sequencing. FEBS Lett. 1978 Mar 1;87(1):107–110. doi: 10.1016/0014-5793(78)80145-8. [DOI] [PubMed] [Google Scholar]
  18. Sidwell R. W., Huffman J. H., Barnett B. B., Pifat D. Y. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother. 1988 Mar;32(3):331–336. doi: 10.1128/aac.32.3.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972 Aug 25;177(4050):705–706. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  20. Streeter D. G., Witkowski J. T., Khare G. P., Sidwell R. W., Bauer R. J., Robins R. K., Simon L. N. Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 1973 Apr;70(4):1174–1178. doi: 10.1073/pnas.70.4.1174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. THOMPSON W. H., KALFAYAN B., ANSLOW R. O. ISOLATION OF CALIFORNIA ENCEPHALITIS GROUP VIRUS FROM A FATAL HUMAN ILLNESS. Am J Epidemiol. 1965 Mar;81:245–253. doi: 10.1093/oxfordjournals.aje.a120512. [DOI] [PubMed] [Google Scholar]
  22. Toltzis P., O'Connell K., Patterson J. L. Effect of phosphorylated ribavirin on vesicular stomatitis virus transcription. Antimicrob Agents Chemother. 1988 Apr;32(4):492–497. doi: 10.1128/aac.32.4.492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wray S. K., Gilbert B. E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985 Feb;5(1):39–48. doi: 10.1016/0166-3542(85)90013-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES